Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, shared a post on LinkedIn about a recent article he and colleagues authored:
“A multinational effort involving over 110 patients investigating the selective RET inhibitor BOS172738.
Whilst a manageable safety profile and promising efficacies were shown, the drug was not chosen to be further developed due to an already competitive landscape.
Thanks, Patrick Schöffski, for spearheading the study and its publication in ESMO – European Society for Medical Oncology.”
Title: BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors, including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study
Authors: P. Schöffski, A. Gazzah, J. Trigo, A. Italiano, P. Gougis, V. Subbiah, J.-Y. Shih, H.H. Loong, B. Doger, M. Keegan, B. Jeglinski, K. Andreas, B.C. Cho
Read the Full Article in ESMO Open.
More posts featuring Herbert Loong on OncoDaily.
